Novacyt S.A.: CTDA Approval of PROmate® COVID-19 1 Gene and Grant of CE Mark for COVID-19 Lateral Flow Self-Test
businesswire.com
news
2022-06-01 00:00:00

June 01, 2022 02:00 AM Eastern Daylight Time PARIS & CAMBERLEY, England--(BUSINESS WIRE)--Regulatory News:

Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) ("Novacyt", the "Company" or the "Group"), an international specialist in clinical diagnostics, announces the approval of its PROmate® COVID-19 1G (q16) Real-Time PCR test (for use on its Q16 instrument), by the UK Health Security Agency's Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 ("CTDA"). The Company also announces that the Company's PathFlow® COVID-19 Rapid Antigen Self-Test has received a CE mark.
